standard statistical software statview-j version 5.0 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
standard statistical software statview-j version 5.0
Standard Statistical Software Statview J Version 5.0, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/standard+statistical+software+statview-j+version+5%2E0/statview+5+0/10__1111_slash_j__1872___034x__2008__00484__x-70-6-11
Average 90 stars, based on 1 article reviews
Standard Statistical Software Statview J Version 5.0, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/standard+statistical+software+statview-j+version+5%2E0/statview+5+0/10__1111_slash_j__1872___034x__2008__00484__x-70-6-11
Average 90 stars, based on 1 article reviews
standard statistical software statview-j version 5.0 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: A novel third generation bisphosphonate, minodronate (YM529), prevented proliferation and migration of hepatocellular carcinoma cells through inhibition of mevalonate pathway Article Snippet: Aim: Skeletal metastases and bone metasitasis are a common occurrence in patients with advanced hepatocellular carcinoma (HCC).. Bisphosphonates (BPs), which are used for the treatment of osteoporosis and tumor-associated hypercalcemia, have recently been reported to decrease skeletal morbidity in patients with metastatic bone disease.. Several studies revealed that nitrogen-containing BPs (N-BPs) could inhibit tumor growth and migration, indicating the possibility that N-BPs have direct inhibitory effects. Article Title: The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Article Snippet: Purpose: Several clinical trials in human neoplasms have demonstrated the effectiveness of combination therapy with 5-fluorouracil (FUra), cisplatin (CDDP), and leucovorin (LV).. Thymidylate synthase (TS), the target enzyme of FUra, and dihydropyrimidine dehydrogenase (DPD), the rate-limiting catabolic enzyme of pyrimidines, have both been reported to be predictors of the response to FUra-based chemotherapies.. Therefore, we aimed to clarify the effects of a combination of the three drugs against hepatoma cells and to determine the role of these two enzymes using in vitro models. |